康弘药业：米拉贝隆缓释片获得药品注册证书

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron extended-release tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating overactive bladder (OAB) symptoms in adults [1] Group 1 - The product is specifically designed for symptomatic treatment of urinary urgency, frequency, and/or urge incontinence in adult patients with OAB [1]